AstraZeneca's oral PCSK9 inhibitor halves cholesterol in phase 2 trial
AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial in patients with a lipid disorder.
AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks at its highest dose, hitting the goal of a phase 2 trial in patients with a lipid disorder.
